about
The value of serologic markers in indeterminate colitis: a prospective follow-up studyProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's diseaseAtonal homolog 1 is a tumor suppressor geneLiver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammationUnique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's diseaseMucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices.Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice.Immunosuppressive activity of a new pteridine derivative (4AZA1378) alleviates severity of TNBS-induced colitis in mice.Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease.Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.Commentary: I see no convincing evidence of "enterocolitis," "colitis," or a "unique disease process".Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series.T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status.Neurotrophins and neurotrophin receptors in proliferative diabetic retinopathy.Role of chemokines in vernal keratoconjunctivitis.High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy.Assessment of histologic disease activity in Crohn's disease: a systematic review.Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier.Medical therapy for Crohn's disease strictures.Crohn's disease and infections: a complex relationship.Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma?Pathology of early lower GI cancer.A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.The role of chemokines and their receptors in uveitis.Indeterminate colitis: a review of the concept--what's in a name?
P50
Q28216203-E19CE1DA-59AD-4298-AFAC-D9617D0A070DQ28255557-14646A67-59BD-4613-BDEE-668D719443AAQ28474993-30292978-E51B-4E31-98EF-AC24DEA8C1F8Q28592904-73D84905-EEE7-42D1-A5CE-A6DCCF53B5FBQ30657855-80194013-C9CA-4447-8C9F-6FCC95B3681EQ30945619-48633B9E-814E-4BDA-BDF0-BA5D4BE8A791Q31148096-8B75E41B-643C-4E65-BD13-FC08FA495716Q33252484-9516AEE0-1B60-4AD5-A744-85D123C8AF40Q33261882-DC322005-4355-4C8E-B0FF-1013FE6CC941Q33766675-00405E04-3FDE-4923-AA03-ADD680129A22Q34145454-5F3B39A2-952D-4723-A08B-33FE45D57777Q34156631-61BC5C8F-05AE-45CF-AD61-49288B5DC115Q34231878-AAE2FF64-546D-4011-9B17-EE7B3A19710DQ34410821-9E3B43E7-3E80-46F7-910A-879A52A051F2Q34610304-133D7E8F-E195-41E2-9A8B-6F5DFA29D488Q34612166-0F34C4D8-9D37-4C64-AAE6-89C498CA88A7Q34769969-0AAAE035-3182-4193-A5F9-8336C37857E6Q35051849-7A5C312E-34E3-4832-8E71-FF0DF52DC285Q35108807-AA4D7697-88EE-48CD-AA1A-8F84B188BE0BQ35228055-B5BF9FB6-0F5F-4D23-92E6-BF4184EA1C40Q35605834-D3006208-CF95-414E-B9FC-0D80C690405BQ35731494-901FAFCE-9B08-4F78-B4F0-EA7FB5BEFDD2Q35936315-31076DB0-3EEE-4058-A266-81BCCC15FA96Q36023527-C8F6FB8D-A426-46FD-A9FD-39F2C4B0EF14Q36336481-6C83245A-5D45-4236-8D19-C697141128E9Q36720362-96083AD8-1EFD-41C2-B761-631761BBFF1FQ36790612-20BB315D-C44B-46FB-878E-74ECBC22A493Q37063113-F06749AF-7D89-4AB6-96B9-9F763EB21C47
P50
description
onderzoeker
@nl
name
Karel Geboes
@ast
Karel Geboes
@en
Karel Geboes
@es
Karel Geboes
@nl
Karel Geboes
@sl
type
label
Karel Geboes
@ast
Karel Geboes
@en
Karel Geboes
@es
Karel Geboes
@nl
Karel Geboes
@sl
prefLabel
Karel Geboes
@ast
Karel Geboes
@en
Karel Geboes
@es
Karel Geboes
@nl
Karel Geboes
@sl